Filtered By:
Drug: Taxotere
Procedure: Gastroschisis Repair
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & amp; therapeutics
Front Oncol. 2023 Aug 17;13:1193736. doi: 10.3389/fonc.2023.1193736. eCollection 2023.ABSTRACTProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate th...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Neha Thakur Sameer Quazi Bindu Naik Saurabh Kumar Jha Pallavi Singh Source Type: research
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Cancer Res Commun. 2023 Aug 15;3(8):1551-1563. doi: 10.1158/2767-9764.CRC-22-0501. eCollection 2023 Aug.ABSTRACTTriple-negative breast cancer (TNBC) constitutes 10%-15% of all breast tumors. The current standard of care is multiagent chemotherapy, which is effective in only a subset of patients. The original objective of this study was to deploy a mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) to identify kinases elevated in non-pCR (pathologic complete response) cases for therapeutic targeting. Frozen optimal cutting temperature compound-embedded core needle biopsies were obtained from 43 patients wit...
Source: Cell Research - August 17, 2023 Category: Cytology Authors: Junkai Wang Alexander B Saltzman Eric J Jaehnig Jonathan T Lei Anna Malovannaya Matthew V Holt Meggie N Young Mothaffar F Rimawi Foluso O Ademuyiwa Meenakshi Anurag Beom-Jun Kim Matthew J Ellis Source Type: research
A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
CONCLUSIONS: Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.PMID:36950270 | PMC:PMC10026109 | DOI:10.1177/17588359231157633
Source: Adv Data - March 23, 2023 Category: Epidemiology Authors: Anna V Tinker Neesha C Dhani Prafull Ghatage Deanna McLeod Vanessa Samou ëlian Stephen A Welch Alon D Altman Source Type: research
< em > Ex Vivo < /em > treatment of coronary artery endothelial cells with serum post-exercise training offers limited protection against < em > in vitro < /em > exposure to FEC-T chemotherapy
Conclusion: FEC-T chemotherapy drugs cause significant damage and dysfunction of endothelial cells. Preconditioning with serum collected after an exercise training intervention, elicited some protection against the usual toxicity of FEC-T, when compared to control serum.PMID:36818448 | PMC:PMC9932712 | DOI:10.3389/fphys.2023.1079983
Source: Cancer Control - February 23, 2023 Category: Cancer & Oncology Authors: Marie Mclaughlin Katie L Hesketh Sarah L Horgan Geraint Florida-James Matthew Cocks Juliette A Strauss Mark Ross Source Type: research
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance
CONCLUSION: This update of the French recommendations should help to improve the management of patients with prostate cancer.PMID:36400484 | DOI:10.1016/j.purol.2022.07.147
Source: Cancer Control - November 18, 2022 Category: Cancer & Oncology Authors: G Ploussard G Roubaud E Barret J-B Beauval L Brureau G Cr éhange C Dariane G Fiard G Fromont M Gauth é R Renard-Penna F Rozet A Ruffion P Sargos R Mathieu M Roupr êt Comit é de Cancérologie de l’Association française d’Urologie, groupe prostate Source Type: research
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark
CONCLUSION: Docetaxel effectiveness was influenced by SNPs in GSTP1, CYP3A, and SLCO1B1 in premenopausal women with non-distant metastatic breast cancer, likely related to altered docetaxel pharmacokinetics. These SNPs may help determine individual benefit from taxane-based chemotherapy.PMID:35501422 | DOI:10.1007/s10549-022-06596-2
Source: Clinical Breast Cancer - May 2, 2022 Category: Cancer & Oncology Authors: Cathrine Fonnesbech Hjorth Per Damkier Tore Bjerregaard Stage S øren Feddersen Stephen Hamilton-Dutoit Mikael R ørth Bent Ejlertsen Timothy Lee Lash Thomas Patrick Ahern Henrik Toft S ørensen Deirdre Cronin-Fenton Source Type: research
Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
Cold Spring Harb Mol Case Stud. 2022 Apr 29:mcs.a006194. doi: 10.1101/mcs.a006194. Online ahead of print.ABSTRACTDefective DNA mismatch repair genes can lead to microsatellite instability (MSI)-high status in prostate cancer (PC). Accumulation of replication errors in DNA leads to the production of abundant neoantigens, which could be targets for immune-checkpoint inhibitors (CPIs). However, the incidence of MSI-high PC is low, and not all patients show a satisfactory therapeutic response to CPIs. Here, we present the case of a patient with MSI-high castration-resistant PC who showed a remarkable and durable response to pe...
Source: Cancer Control - April 29, 2022 Category: Cancer & Oncology Authors: Kosuke Shimizu Takeshi Sano Kei Mizuno Takuro Sunada Noriyuki Makita Hiroki Hagimoto Takayuki Goto Atsuro Sawada Masakazu Fujimoto Kentaro Ichioka Osamu Ogawa Takashi Kobayashi Shusuke Akamatsu Source Type: research
